Rosenbloom, Michael H.
O’Donohue, Tricia
Zhou-Clark, Domi
Mala, Deepashni
Frazier, Andrew
Tarrant, Michael
Modrijan, Michelle
Riveira, Melora
Chapman, Darla
Griffin, Yvonne
Shakalis, Lauren
Grabowski, Thomas J.
Article History
Accepted: 13 May 2024
First Online: 5 June 2024
Declarations
:
: Open access funded by UW Department of Neurology.
: Dr. Rosenbloom has served as a consultant for Eisai. Tricia O’Doohue has no conflicts to declare. Lauren Shakalis has no conflicts to declare. Deepashni Mala has no conflicts to declare. Andrew Frazier has no conflicts to declare. Michael Tarrant has no conflicts to declare. Michelle Modrijan has no conflicts to declare. Melora Riveira has no conflicts to declare. Darla Chapman has no conflicts to declare. Yvonne Griffin has no conflicts to declare. Domi Zhou-Clark has no conflicts to declare. Thomas J. Grabowski has no conflicts to declare.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Dr. Rosenbloom was the primary writer and contributor to the manuscript. Tricia O’Donohue was part of the lecanemab implementation team. Lauren Shakalis was part of the lecanemab implementation team. Deepashni Mala was part of the lecanemab implementation team. Andrew Frazier was part of the lecanemab implementation team. Michael Tarrant was part of the lecanemab implementation team. Michelle Modrijan was part of the lecanemab implementation team. Melora Riveira was part of the lecanemab implementation team. Darla Chapman was part of the lecanemab implementation team. Yvonne Griffin was part of the lecanemab implementation team. Domi Zhou-Clark was part of the lecanemab implementation team and created figures for the manuscript. Thomas J. Grabowski reviewed and edited the manuscript. All authors have read and approve the final manuscript and agree to be accountable for the work.
: Not applicable.